Lunai Bioworks Stock (NASDAQ:RENB)

Ownership Financials Chart

Previous Close

$0.19

52W Range

$0.17 - $2.10

50D Avg

$0.26

200D Avg

$0.57

Market Cap

$42.26M

Avg Vol (3M)

$1.35M

Beta

0.53

Div Yield

-

RENB Company Profile

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

25

IPO Date

Feb 07, 2018

Website

RENB Performance

RENB Financial Summary

	Jun 24	Jun 23	Jun 22
Revenue	-	-	-
Operating Income	$-81.64M	$-38.56M	$-116.08M
Net Income	$-80.65M	$-39.68M	$-113.43M
EBITDA	$-81.52M	$-19.48M	$-22.58M
Basic EPS	$-0.84	$-0.71	$-2.16
Diluted EPS	$-0.84	$-0.71	$-2.16

Fiscal year ends in Jun 24 | Currency in USD